Cinta Albacar

Abstract GS1-06: Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study

A. Llombart-Cussac, J. M. Pérez-García, M. Ruiz-Borrego, A. Stradella et autres

es, it, us (code pays fourni par la source)

A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

Shelley Potter, Kerry Avery, Rosina Ahmed, Jana de Boniface et autres

gb, in, se, ch, at, us, jp, il, nl, kr, Éthiopie, be, gr, it, au, Égypte, es, br, ru, ar, tr, pk, de, ca, th, ro, mt, hr, uy, cn, hk, cy, pt (code pays fourni par la source)

Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial

Joan Albanell, Aleix Prat, María Teresa Martínez, Guillermo Villacampa et autres

Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

Géraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen et autres

be, es, it, fr, de, gb, pt (code pays fourni par la source)

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego, Marco Colleoni et autres

es, it, fr, de, be, gb, pt (code pays fourni par la source)

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).

Javier Cortés, José Manuel Pérez-García, Manuel Ruíz-Borrego, Agostina Stradella et autres

es, it, be, fr, gb (code pays fourni par la source)

Abstract OT2-08-02: SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC)

Eva Ciruelos, Antonia Perelló, Santiago González-Santiago, Ana López et autres

es, gb (code pays fourni par la source)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Ariadna Tibau, María Teresa Martínez, Manuel Ramos, Luis de la Cruz‐Merino et autres

es, ie (code pays fourni par la source)

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Antonio Llombart‐Cussac, Joseph Gligorov, Serena Di Cosimo, Cinta Albacar et autres

es, fr, it, pt, ch (code pays fourni par la source)

332TiP SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC)

Eva Ciruelos, Sònia Pernas, Antonia Perelló, A. López et autres

es (code pays fourni par la source)

Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients

Josep Gumà, Jose Adriá-Cebrián, Belen Ruiz-Aguado, Cinta Albacar et autres

es, cn (code pays fourni par la source)

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego, Agostina Stradella et autres

es, us, be, gb, de, fr, it, pt (code pays fourni par la source)